Affiliation: Columbia University
- Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patientsA Swaminath
Division of Digestive and Liver Diseases, Columbia University Presbyterian Hospital, New York, NY 10032, USA
Aliment Pharmacol Ther 29:273-8. 2009..Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab...
- Effect of physician education and patient counseling on inpatient nonsurgical percutaneous feeding tube placement rate, indications, and outcomeArun Swaminath
Division of Gastroenterology, Columbia University Presbyterian Hospital, New York City, NY 10032, USA
South Med J 103:126-30. 2010..We assessed the effect of physician education and counseling for patients and their surrogates on inpatient nonsurgical (endoscopic and radiologic) PFT placement rates, indications, complications, and mortality...
- Video capsule endoscopy in inflammatory bowel disease: past, present, and future reduxArun Swaminath
Department of Medicine, Division of Gastroenterology and Hepatology, Columbia University Medical Center, New York, New York 10032, USA
Inflamm Bowel Dis 16:1254-62. 2010....
- Use of video capsule endoscopy in Crohn's diseaseA Swaminath
Department of Medicine, Columbia University Medical Center, New York, NY, USA
Minerva Gastroenterol Dietol 56:437-49. 2010..We will focus on comparative imaging data, how capsule endoscopy may aid in the prediction of disease type and course, the avoidance and meaning of capsule retention, along with cost considerations, and directions for the future...
- Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-expertsArun Swaminath
Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, 622 West 168th Street, PH 20 303, New York, NY 10032, USA
Dig Dis Sci 56:1160-4. 2011..There are no guidelines to clarify which of the drugs may be better suited to individual clinical scenarios...
- Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximabArun Swaminath
Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
J Clin Rheumatol 17:281-3. 2011..Treatment with anti-B-cell therapy may be a new treatment option for patients with gammopathy-associated leukocytoclastic vasculitis...
- Peripheral neuropathic symptoms in celiac disease and inflammatory bowel diseaseTing Chin David Shen
Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA
J Clin Neuromuscul Dis 13:137-45. 2012..An association between celiac disease (CD) and peripheral neuropathy (PN) has been reported...
- Optimizing drug therapy in inflammatory bowel diseaseArun Swaminath
Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1069, New York, NY 10029, USA
Curr Gastroenterol Rep 9:513-20. 2007..Lastly, additional information regarding the optimal method for using anti-tumor necrosis factor therapy continues to accumulate...
- Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitisArun Swaminath
Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA
Inflamm Bowel Dis 14:213-6. 2008..Although the TREAT registry has shown systemic infliximab to be safe in the long term, there is concern regarding infectious as well as neoplastic complications...